Rising Cash Burn Will Hamper RNA Editing Yet Spark Hope
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
07 Aug 25
Updated
10 Aug 25
AnalystLowTarget's Fair Value
US$9.00
5.7% overvalued intrinsic discount10 Aug
US$9.51
1Y
62.6%7D
8.6%